دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Caring for carers of people with cancer
doi : 10.1016/S1470-2045(24)00588-6
Volume 25, Issue 11, November 2024, Page 1387
The state of the science of oral selective oestrogen receptor degraders
Kristina Fanucci a b, Erica L Mayer a b
The hidden barriers to using cancer registration data
Nicola Hughes a, Richard Feltbower b, Dan Stark a
Radiotherapy and theranostics in a changing world
Cheryl Lai a, Smriti Patodia a, David Collingridge a
Spillover benefits of workforce capacity building in radiotherapy
Wilfred Ngwa a, Twalib Ngoma b
Radiotherapy gaps and new frontiers in the Commonwealth
Mei Ling Yap a b c, Danielle Rodin d e
Focus where it matters: turning insights into advocacy
John Christodouleas a b, Therese Lindé c, Gustaf Salford c
Radiotherapy and conflict: from disruption to expansion and hope
Nazik Hammad a, Fidel Rubagumya b
Celiac plexus radiosurgery for retroperitoneal pain syndrome
Ertugrul Senturk a, Serap Catli Dinc a
Celiac plexus radiosurgery for retroperitoneal pain syndrome – Authors' reply
Yaacov R Lawrence a b, Ronen Fluss c, Laurence S Freedman c, Zvi Symon a b
Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer?
Ryan Huey a, Kanwal Raghav a
Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer? – Authors' reply
Xichun Hu a b, Shiyu Jiang a b, Xin Liu a b
PSMA-PET research: addressing challenges and prospects
Hantong Hu a
PSMA-PET research: addressing challenges and prospects
Dan Shan a
PSMA-PET research: addressing challenges and prospects – Authors' reply
Boris A Hadaschik a, Madeleine J Karpinski b c, Johannes Hüsing c, Wolfgang P Fendler b
Concerns regarding the AtTEnd trial in advanced endometrial carcinoma
Queran Lin a, Wenyi Jin b, Dan Shan c
Concerns regarding the AtTEnd trial in advanced endometrial carcinoma
Ze Xiang a, Jian Wu b
Concerns regarding the AtTEnd trial in advanced endometrial carcinoma – Authors' reply
Elena Biagioli a, Eliana Rulli a, Roldano Fossati a, Nicoletta Colombo b c
Omitting study limitations might have implications for the patients
Paul de Boissieu a, Sylvie Chevret b c
Omitting study limitations might have implications for the patients – Authors' reply
Jean-Yves Blay a, Sylvie Chabaud a, David Perol a, Axel Le Cesne b
[18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer
Xiaoling Xu a, Lisha Ye b, Jinpeng Shi c, Huihui Li b, Yong Fang d
[18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer
Sarah Bowen Jones a, Saskia Cooke b, José Belderbos b, Corinne Faivre-Finn a c
[18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer – Authors' reply
Sébastien Thureau a, Philippe Giraud b, Gérard Zalcman c, Pierre Vera d
Organisations withdraw from cancer conference over tobacco link
Emma Wilkinson
AACR highlights advances and threats to US cancer research
Tony Kirby
Jordan joins the Global Platform for Access to Childhood Cancer Medicines
Elizabeth Gourd
UK NHS cancer patients to be among those benefiting from deal with life sciences industry
Tony Kirby
The Biden administration curbs cancer drug costs for Medicare patients
Bryant Furlow
Abortion restrictions have a negative impact on cancer care
Sharmila Devi
Renewed collaboration aims to improve cancer outcomes in South America
Manjulika Das
US legislation might soon allow easier access to cancer medications
Karl Gruber
Cancer control in the Commonwealth: a roadmap
Rifat Atun a b c, Bhawna Sirohi d, Che Reddy a b, Mary Gospodarowicz e
Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis
Harriet Rumgay PhD a, Suzanne T Nethan MDS b, Richa Shah PhD a, Jérôme Vignat MSc a, Prof Olalekan Ayo-Yusuf PhD c †, Prof Pankaj Chaturvedi MS d †, Prof Eliete N S Guerra PhD e †, Prakash C Gupta PhD f †, Ruchika Gupta MD g †, Shiwei Liu PhD h †, Cecilia Magnusson PhD i †, Mark Parascandola PhD j †, Yvette C Paulino PhD k †, Negar Rezaei PhD l †, Prof Kamran Siddiqi PhD m †, Prof Saman Warnakulasuriya DSc n o †, Beatrice Lauby-Secretan PhD b, Isabelle Soerjomataram PhD a
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
Mafalda Oliveira MD a, Denys Pominchuk PhD b, Prof Zbigniew Nowecki MD c, Erika Hamilton MD d, Yaroslav Kulyaba MD e, Timur Andabekov PhD f, Prof Yevhen Hotko MD g, Tamar Melkadze MD h, Prof Gia Nemsadze MD i, Prof Patrick Neven MD j, Vladimir Vladimirov MD k, Claudio Zamagni MD l, Hannelore Denys MD m, Frédéric Forget MD n, Zsolt Horvath MD o, Alfiya Nesterova MD p, Maxine Ajimi PhD q, Bistra Kirova MBChB r, Teresa Klinowska PhD s, Justin P O Lindemann MBChB q…Ekaterine Arkania MD v
Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy study
Dianna L Ng MD a b e, Prof Edda Vuhahula PhD f, Asteria H Kimambo MD f, Marie Claire Ndayisaba MD f, Godfrey S Philipo MD h, Beatrice P Mushi MD h, Kenneth E Ho BS i, Alan Paciorek BS c, Zainab Illonga MD h, Prof Li Zhang PhD b c d, Poonam Vohra MD a, Jodi Weidler PharmD j, Michael Bates MD j, Elia J Mmbaga MD g k, Prof Katherine Van Loon MD b d
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
Prof Mariano Provencio MD a, Ernest Nadal MD c, Amelia Insa d, Rosario GarcÃa Campelo MD e, JoaquÃn Casal MD f, Manuel Dómine MD g, Bartomeu Massuti MD h, Margarita Majem MD i, Delvys RodrÃguez-Abreu MD j, Alex MartÃnez-Martà MD k, Javier de Castro MD l, David Gómez de Antonio MD b, Iván Macia MD c m n o, Santiago Figueroa MD d, LuÃs Fernández Vago MD e, Virginia Calvo MD a, Ramón Palmero MD c, Belén Sierra-Rodero MSc a, Cristina MartÃnez-Toledo MSc a, Marta Molina-Alejandre MSc a…Alberto Cruz-Bermúdez PhD a
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
Antonio D'Alessio MD a, Bernardo Stefanini MD a d, Julia Blanter MD e, Benjamin Adegbite MD e, Fionnuala Crowley MD e, Vincent Yip MD f, Sarah Slater MD g, Claudia Angela Maria Fulgenzi MD a, Ciro Celsa MD PhD a h, Giulia Francesca Manfredi MD a c, Madhava Pai MD b, Prof Robert D Goldin MD i, Stephen C Ward MD PhD j, Maria Isabel Fiel MD j, Daniel H Shu MD k, Yung-Yeh Su MD PhD l m n, Alessio Cortellini MD PhD a o, Marina Baretti MD k, Robert Anders MD k, Mark Yarchoan MD k…David J Pinato MD PhD a c
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis
Ashley Jackson BSc a, Pradeep S Virdee PhD b, Sharon Tonner PhD b, Jason L Oke PhD b c, Prof Rafael Perera PhD b, Kaveh Riahi BA d, Ying Luan PhD e †, Sara Hiom MSc d, Harpal Kumar MBA d, Harit Nandani MS g, Kathryn N Kurtzman MD f, Prof Dyfed Huws FFPH h i, Dawn Allan MSc h, Stephanie Smits PhD h, Sean McPhail PhD j, Eileen E Parkes PhD a, Prof F D Richard Hobbs FMedSci b, Prof Mark R Middleton PhD a, Brian D Nicholson PhD b
Access to diagnostic imaging and radiotherapy technologies for patients with cancer in the Baltic countries, eastern Europe, central Asia, and the Caucasus: a comprehensive analysis
Prof Manjit Dosanjh PhD a b, Prof Vesna Gershan PhD c, Eugenia C Wendling BSc b, Prof Jamal S Khader MD d, Taofeeq A Ige PhD e, Prof Mimoza Ristova PhD f, Richard Hugtenburg PhD g h, Petya Georgieva MSc i, C Norman Coleman MD b, David A Pistenmaa MD b, Gohar H Hovhannisyan PhD j, Prof Tatul Saghatelyan MD k, Prof Kamal Kazimov MD l, Prof Rovshan Rzayev PhD m, Gulam R Babayev PhD n, Mirzali M Aliyev MSc o, Eduard Gershkevitsh PhD p, Prof Irina Khomeriki PhD q, Prof Lily Petriashvili PhD r, Prof Maia Topeshashvili MD s…Suvsana M Talibova MD ae
Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data
Marie Lund PhD a b c, Giulia Corn PhD a d, Maj-Britt Jensen MSc g, Tonny Petersen PhD b c, Prof Kim Dalhoff DMSc b c, Prof Bent Ejlertsen DMSc c g h, Prof Lars Køber DMSc c i, Jan Wohlfahrt DMSc e, Prof Mads Melbye DMSc c f j k
Radiotherapy and theranostics: a Lancet Oncology Commission
Prof May Abdel-Wahab MD a, Prof Francesco Giammarile MD PhD a, Mauro Carrara PhD a, Diana Paez MD a, Prof Hedvig Hricak MD PhD b c d f, Nayyereh Ayati PhD g, Jing Jing Li MCE g, Malina Mueller PhD h, Prof Ajay Aggarwal MD PhD j, Prof Akram Al-Ibraheem MD k l, Sondos Alkhatib MD m, Prof Rifat Atun PhD n o p, Abubakar Bello MD q, Daniel Berger PhD a, Prof Roberto C Delgado Bolton MD PhD r s, Prof John M Buatti MD t, Prof Graeme Burt PhD u, Olivera Ciraj Bjelac PhD a, Lisbeth Cordero-Mendez MD a, Prof Manjit Dosanjh PhD v w…Prof Andrew M Scott MD ba bb bc bd
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements
Javier E Villanueva-Meyer MD a b, Spyridon Bakas PhD c d e f g h, Pallavi Tiwari PhD i, Prof Janine M Lupo PhD a, Evan Calabrese MD PhD j, Prof Christos Davatzikos PhD k l, Wenya Linda Bi MD PhD m, Marwa Ismail PhD i, Hamed Akbari MD PhD ad, Philipp Lohmann PhD p q, Thomas C Booth MD r s t, Benedikt Wiestler MD u, Prof Hugo J W L Aerts PhD o ae, Ghulam Rasool PhD ab, Prof Joerg C Tonn MD v, Prof Martha Nowosielski PhD w, Prof Rajan Jain MD x, Prof Rivka R Colen MD ae, Sarthak Pati MS c, Ujjwal Baid PhD c…Prof Norbert Galldiks MD p ac
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice
Spyridon Bakas PhD a b c d e f, Prof Philipp Vollmuth MD MBA g h i, Prof Norbert Galldiks MD j k, Thomas C Booth MD PhD l m, Hugo J W L Aerts PhD n p q, Wenya Linda Bi MD PhD o, Benedikt Wiestler MD PhD r, Pallavi Tiwari PhD s, Sarthak Pati MSc a, Ujjwal Baid PhD a b e, Evan Calabrese MD PhD t, Philipp Lohmann PhD j w, Martha Nowosielski MD PhD x, Prof Rajan Jain MD y, Prof Rivka Colen MD z, Marwa Ismail PhD s, Ghulam Rasool PhD ag, Prof Janine M Lupo PhD u, Hamed Akbari MD PhD aa, Prof Joerg C Tonn MD ab ac…Raymond Y Huang MD PhD n
Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE
Prof Philippe Morice MD a b, Prof Giovanni Scambia MD c, Prof Nadeem R Abu-Rustum MD e, Prof Maribel Acien MD f g, Alessandro Arena MD h i, Prof Sara Brucker MD j k, Prof Ying Cheong MD l, Prof Pierre Collinet MD m, Francesco Fanfani MD c, Francesca Filippi MD n, Prof Ane Gerda Zahl Eriksson MD o, Prof Sebastien Gouy MD a b, Prof Philipp Harter MD p, Prof Xavier Matias-Guiu MD q, George Pados MD r, Maja Pakiz MD s, Prof Denis Querleu MD d, Prof Alexandros Rodolakis MD t, Christine Rousset-Jablonski MD u v, Artem Stepanyan MD w…Prof Michaël Grynberg MD b ab ac
Interchangeability of immune checkpoint inhibitors: an urgent need for action
Michiel Zietse PharmD a, Roelof W F van Leeuwen PhD a b, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani PhD c d, Jolanda E de Boer MSc e, Rudy Dupree MSc e, Prof Ron H J Mathijssen MD b, Lonneke Timmers PhD e f
